Blood tests being studied to help detect ovarian cancer
Compares investigational blood tests in women with and without ovarian cancer.
Plain-language title generated from the registry record
Registry title: Innovative Ovarian Cancer Biomarker Assays
Key facts
- Where
- Kaunas, LithuaniaSee the site
Where in Lithuania
- Lithuanian University of Health SciencesKaunas, LithuaniaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National and Kapodistrian University of Athens
- Trial code
- NCT07693894
- Record updated
- 1 October 2026
- Original description
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.Read full original descriptionShow less
Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.
Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.
The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.
The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.
This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.
Inclusion: EOC patients; Women, trans men and non-binary people with female reproductive organs; Aged ≥35 years*; Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment; Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC); Able to give informed consent; Healthy controls; Women, trans men and non-binary people with female reproductive organs; Aged ≥35 years; No cancer history; Able to give informed consent.
Exclusion: Prior history and any treatment for malignancy; Prior removal of either ovary for any reason; Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements; Pregnant or lactating.